PROPANC BIOPHARMA INC (PPCB) Stock Overview
USA - NASDAQ:PPCB - US74346N7012 - Common Stock
PPCB Key Statistics, Chart & Performance
The current stock price of PPCB is 1.52 USD. In the past month the price decreased by -16.48%.
PPCB Latest News, Press Relases and Analysis
PPCB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Related stock screener links
About PPCB
Company Profile
Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The firm has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.
Company Info
PROPANC BIOPHARMA INC
302/6 Butler Street, Camberwell
Melbourne VICTORIA AU
Employees: 2
Phone: 61398820780
PROPANC BIOPHARMA INC / PPCB FAQ
Can you describe the business of PROPANC BIOPHARMA INC?
Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The firm has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.
Can you provide the latest stock price for PROPANC BIOPHARMA INC?
The current stock price of PPCB is 1.52 USD. The price increased by 2.7% in the last trading session.
Does PROPANC BIOPHARMA INC pay dividends?
PPCB does not pay a dividend.
What is the ChartMill technical and fundamental rating of PPCB stock?
PPCB has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What sector and industry does PROPANC BIOPHARMA INC belong to?
PROPANC BIOPHARMA INC (PPCB) operates in the Health Care sector and the Biotechnology industry.
What is the Short Interest ratio of PROPANC BIOPHARMA INC (PPCB) stock?
The outstanding short interest for PROPANC BIOPHARMA INC (PPCB) is 4.76% of its float.
PPCB Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PPCB.
PPCB Financial Highlights
Over the last trailing twelve months PPCB reported a non-GAAP Earnings per Share(EPS) of -703.62. The EPS increased by 98.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2147.26% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |